American Academy of Dermatology Annual Meeting
Prepared by Song Park, Paul Nghiem, Tomoko Akaike and Coley Doolittle-Amieva
1) 1st International Symposium on Merkel Cell Carcinoma – October 21-22, 2019, Moffitt Cancer Canter, Tampa, FL
This conference is a first-of-its kind gathering of thought leaders and active investigators in MCC. The goals are to share new unpublished scientific developments, promote scientific discourse, and establish new collaborations that can improve our understanding of MCC biology, pathogenesis, and therapy. Detailed program and information can be found at https://moffitt.org/for-healthcare-providers/continuing-education/provider-conferences/international-symposium-on-merkel-cell-carcinoma/ . If you are interested in attending this meeting or have specific questions, please contact Dr. Tsai (Kenneth.Tsai@moffitt.org). Abstract submission deadline is May 31, 2019. Some trainee fellowships will be made available for excellent abstract submissions.
2) Video of Plenary Lecture, “Less toxic, more effective: A win-win for Merkel cell carcinoma patients”, by Paul Nghiem at the 2019 AAD Annual Meeting is available at https://merkelcell.org/news-and-publications/2019/american-academy-of-dermatology-2019-plenary-session/
3) If you are interested in presenting at next year’s MMIG meeting in Denver, CO, on Friday March 20, 2020 (5 – 7 pm), please send Paul an email (firstname.lastname@example.org) with a proposed topic that is relevant to MCC patient care or translational research.
Speakers/Topics (detailed in following pages):
Michael Tetzlaff (MD Anderson)
– Original publication from Dr. Tetzlaff
Feldmeyer L et al., Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma, Clin Cancer Res. 2016 Nov 15;22(22):5553-5563.
– Al-Rohil RN et al., Intratumoral and peritumoral lymphovascular invasion detected by D2-40 immunohistochemistry correlates with metastasis in primary cutaneous Merkel cell carcinoma, Hum Pathol. 2018 Jul;77:98-107.
Isaac Brownell & Natasha T Hill (NIH)
A perinuclear dot-like pattern of cytokeratin20 (CK20) expression is a pathognomonic finding for MCC. However, some MCC tumors are negative for CK20 or have a diffuse cytoplasmic pattern. With the help of Dr. Paul Harms, Drs. Brownell and Hill assessed the expression pattern of cytokeratins in MCPyV-positive (VP) and MCPyV-negative (VN) MCC tumors. Overall 94% of MCC tumors had some cells with dot-like staining. All VP-MCC had areas of dot-like staining, whereas 7 of 53 (13%) of VN-MCC completely lacked dot-like staining.
Coley Doolittle-Amieva & Song Park (University of Washington)
Vishal Patel (George Washington University)
Dr. Patel introduced SCOUT, a new consortium physician from multiple specialties who are expert in the study of non-melanoma skin cancer including squamous cell carcinoma and Merkel cell carcinoma. Dr. Chrysalyne Schmults (BWH) is a co-founder of SCOUT.
David Miller (MGH)
MCC is a rare cancer, and current clinical outcomes research on MCC are limited to large administrative data sets (e.g. NCDB), which often lack nuanced clinical information, or single-institution databases. The relatively small number of MCC patients dispersed in multiple institutions could potentially limit future development of drugs due to the difficulty of meeting significant “n” for approval.
The PDS MCC Registry is a multi-institutional collaborative effort that will prospectively follow and record outcome and events in MCC patients. It will adopt new methodologies, that will enable multiple investigators to examine real world outcome data in real time. Data from the Registry could be used to determine: (i) precise patient stratification into risk categories, (ii) identification of best practices, (iii) revelations about optimal sequence and combinations therapies, (iv) uncovering low incidence toxicities and (v) the generation of novel testable hypotheses. Importantly, the Registry offers a way forward in the yet-unsolved dilemma of drug development for rare tumors since the Registry’s design will allow for the creation of highly defined patient-level data that can be used as a robust comparator for single arm Phase I-II clinical trials.
The MCC Task Force comprises members from academic medical centers, the drug industry, the NIH and FDA. Project Data Sphere provides a secure, open-access data sharing platform designed to optimize research and yield rigorous and timely results. The Registry is utilizing REDCap as the electronic data collection system. The Task Force team is currently building consensus data fields, and will set up a detailed plan of data access model, etc. Test of a beta version and development of data quality plan and usage agreements are soon to be executed.
If you are interested in participating in this project, please contact Dr. David Miller at DMILLER4@mgh.harvard.edu
In attendance at the 2019 Washington, D.C. MMIG meeting
*= Joined online via Zoom
Afanasiev, Olga (Stanford University)
Akaike, Gensuke (University of Washington) *
Akaike, Tomoko (University of Washington)
Baker, Mairead (National Health Institute) *
Berg, Dan (University of Washington) *
Blenkiron, Cherie (University of Auckland) *
Blom, Astrid Ambroise Paré Hospital (AP-HP)
Brownell, Isaac (National Institute of Health)
Cook, Mac (University of Washington) *
Doolittle-Amieva, Coley (University of Washington)
Forero, Diaya (FUCS)
Frezza, Michael (EMD Serono)
Garman, Khalid *
Guitera, Pascale (Melanoma Institute Australia)
Hill, Natasha (National Institute of Health)
Horne, Michelle (Merck)
Kasturi, Vijay (EMD Serono)
Kudchadkar, Ragini (Emory University)
Kuhns, Jennifer (EMD Serono)
Lango, Miriam (Fox Chase Cancer Center) *
Lu, Steve (Johns Hopkins School of Medicine)
MacKenzie Ross, Alastair (Guy’s and St. Thomas’, London, UK) *
Marcazzan, Sabrina *
Miao, Lingling (National Institutes of Health)
Miller, David (BIDMC/MGH, Harvard)
Nagase, Kotaro (Japan)*
Nghiem, Paul (University of Washington)
Park, Song (University of Washington)
Patel, Vishal (George Washington University)
Perlis, Clifford (Abington Hospital Jefferson)
Silk, Anne (DFCI/BWH) *
Sober, Arthur (Massachusetts General Hospital)
Sunshine, Joel (Northwestern University Feinberg School of Medicine)
Takuria, Manisha (DFCI/BWH)
Tarabadkar, Erica (University of Washington)
Tetzlaff, Michael (MD Anderson)
Weiss, Jonathan (BIDMC/Harvard)
Goals of the Merkel cell carcinoma Multi-center Interest Group (MMIG)
– Promote communication and collaborative studies on MCC
– Enhance access to patient data and specimens
– Expand evidence-based care for MCC
The homepage for MMIG is available at:
MMIG is funded in part by donations from Merkel cell carcinoma patients.
Please note that in many cases, these summaries reflect unpublished data and are provided to help MMIG members manage their patients and give an overview of what is being done at different centers for care and research.Download PDF
The authoritative source on Merkel cell carcinoma.
January 21, 2020